Answers are grounded in this paper and cite their sources.
Comparative study reveals favorable shifts in adipokines and inflammatory markers with canagliflozin in type 2 diabetes, suggesting enhanced cardiovascular and metabolic protection.
These results indicate that canagliflozin may improve adipose tissue function and induce changes in serum leptin, adiponectin, and IL-6 that favorably impact insulin sensitivity and cardiovascular disease risk.
No takes yet. Share an insight, caveat, or question.
Garvey et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: